CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 442 enrolled
Drug / intervention
raltegravirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00751530
NCT00751530N/ACompleted
CompareCT.gov

Outcomes of Early Raltegravir Experience: Comparison of Virologic Response in Regimens Not Containing a Protease Inhibitor in the Antiretroviral Background Regimen Versus a Protease Inhibitor in the Background Regimen

Community Research Initiative of New England·observational·Posted Sep 12, 2008·Updated Jul 2, 2017

In Brief

An observational study evaluating raltegravir for HIV Infections. Completed, enrolled 442 participants across 15 sites.

Detailed Summary

This is a retrospective chart review of participants in raltegravir expanded access program and will compare virologic response in regimens not containing a protease inhibitor in the antiretroviral background regimen to regimens containing a protease inhibitor in the background regimen.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2008
Enrollment StartMar 1, 2008
Primary CompletionJun 15, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.8 years ago

Interventions

raltegravirdrug

New combination ART incorporating raltegravir with other ARVs.